IN THE MEDIA
Mark Trusheim coauthored the article “Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions” published in Science Direct: Drug Discovery Today, November 24, 2020. This review alerts developers on how to address challenges that complicate gene therapy medicinal products receiving marketing authorization.

Mark was also quoted in “Gene Therapy Shows Promise for a Form of Blindness, but Is It a Cure? Study of treatment for an inherited form of vision loss raises pricing questions for drugs with long-term benefits” by Amy Dockser Marcus in the Wall Street Journal on December 9, 2020, and in “Innovative payment models to support cell and gene therapies on the rise” by Anuja Vaidya in MedCity News on December 9, 2020. 

IN THE COMMUNITY

Mark Trusheim joined the MACPAC Technical Advisory Panel to explore specific models to help states manage their Medicaid drug spending. MACPAC will convene the advisory panel for three virtual discussions between October and January. Topics will include the current drug pipeline and potential effects on Medicaid costs, alternative payment models for high-cost drugs, and opportunities and barriers associated with those models.

Mark also participated in the APEC Virtual Policy Dialogue on Rare Diseases in Chile & the Asia-Pacific cohosted by The APEC Rare Disease Network and the Chile Ministry of Health on December 9 and 10, and again on December 15 hosted by the Malaysia Ministry of Health. 

…and Mark participated in the virtual MedCity INVEST Precision Medicine conference, December 9-11. 

Coming up…
Mark Trusheim will participate as a panelist in the BioNJ Cell & Gene Therapy Market Access Program on February 17, 2021. The program is recommended for legal, compliance and regulatory professionals within the pharma/biotech industry.